Johnson & Johnson (JNJ) Total Liabilities (2009 - 2026)
Johnson & Johnson (JNJ) posted Total Liabilities of $116.1 billion for Q2 2026, down 3.02% sequentially from $119.7 billion in Q1 2026, and up 1.02% YoY from $114.9 billion in Q2 2025.
Johnson & Johnson (JNJ) Total Liabilities (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Total Liabilities for 18 years, with the latest figure at $116.1 billion in Q2 2026.
- Quarterly Total Liabilities rose 1.02% year-over-year to $116.1 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $116.1 billion (up 1.02% YoY) and the FY2025 annual result came in at $117.7 billion, up 8.33% from the prior year.
- Total Liabilities declined to $116.1 billion in Q2 2026 per JNJ's latest filing, from $119.7 billion in the prior quarter.
- Over five years, Total Liabilities peaked at $125.1 billion in Q2 2023 and troughed at $94.8 billion in Q4 2023.
- A 5-year average of $109.7 billion and a median of $109.6 billion in 2024 frame the typical range for Total Liabilities.
- The sharpest annual moves came in 2023 and 2024: Total Liabilities gained 20.7% in 2023, then dropped 18.51% in 2024.
- Over 5 years, Total Liabilities stood at $100.5 billion in 2022, then fell by 1.73% to $98.8 billion in 2023, then rose by 9.95% to $108.6 billion in 2024, then rose by 8.33% to $117.7 billion in 2025, then slipped by 1.34% to $116.1 billion in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $116.1 billion, $119.7 billion, and $117.7 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 150.01 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 116.09 Bn |
| Mar 29, 2026 | 119.71 Bn |
| Dec 28, 2025 | 117.67 Bn |
| Sep 28, 2025 | 113.54 Bn |
| Jun 29, 2025 | 114.92 Bn |
| Mar 30, 2025 | 115.56 Bn |
| Dec 29, 2024 | 108.61 Bn |
| Sep 29, 2024 | 108.13 Bn |
| Jun 30, 2024 | 109.55 Bn |
| Mar 31, 2024 | 101.95 Bn |
| Dec 31, 2023 | 98.78 Bn |
| Oct 1, 2023 | 94.83 Bn |
| Jul 2, 2023 | 115.28 Bn |
| Apr 2, 2023 | 125.10 Bn |
| Jan 1, 2023 | 110.57 Bn |
| Oct 2, 2022 | 100.53 Bn |
| Jul 3, 2022 | 101.37 Bn |
| Apr 3, 2022 | 103.65 Bn |
| Jan 2, 2022 | 108.00 Bn |
| Oct 3, 2021 | 108.96 Bn |